Evidence map›Paper›PMID 40344620›Full record

SynthesisCancer reports (Hoboken, N.J.)2025

Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose-Response Meta-Analysis.

Mohamed Badie Ahmed, Emad Naem, Harman Saman, Abeer Alsherawi, Asma Syed, Noora Al-Abdulla, Latifa Alkaabi, Mahmoud A Zirie, Suhail A Doi

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamed Badie AhmedDepartment of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.ORCID 0000-0001-8727-9101
Emad NaemEndocrinology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Harman SamanDepartment of Medicine, Hazm Mebaireek Hospital, Hamad Medical Corporation, Doha, Qatar.
Abeer AlsherawiDepartment of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.
Asma SyedDepartment of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.
Noora Al-AbdullaDepartment of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.
Latifa AlkaabiDepartment of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.
Mahmoud A ZirieEndocrinology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Suhail A DoiDepartment of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.

Funding

Qatar National Library
6 · The paper itself

Abstract

introductionDifferentiated thyroid cancer has become a prevalent malignant tumor, particularly papillary thyroid carcinoma (PTC), constituting over 90% of cases. Most PTC lesions are asymptomatic and remain subclinical throughout life, and active surveillance is now being used to monitor the progression of these lesions and intervene when appropriate. This evidence synthesis aims to assess PTC progression in size over time during active surveillance in terms of PTC tumor size progression to or beyond 3 mm during the surveillance period.

methodsA dose-response meta-analysis was conducted using the robust error meta-regression method, using time as the "dose" and cumulative progression (%) was assessed. A comprehensive literature review was done using PubMed/MEDLINE and EMBASE from inception till August 2024.

resultsA total of 21 studies from 7 different countries, including 14 648 participants, were included. Incident progression at 2 years of follow-up was 1%, and this increased linearly to 12% at 20 years of follow-up.

conclusionIt was concluded that progression over the threshold increases linearly over time at approximately less than 1% per year. Therefore, size progression beyond the threshold occurs in a minority and in less than one eighth of subjects by two decades of follow-up.

Indexed as

Thyroid Cancer, PapillaryThyroid NeoplasmsWatchful WaitingDisease ProgressionHumansTumor Burdenactive surveillancedose–response meta‐analysispapillary thyroid cancertumor progression

Identifiers

PMID40344620
PMCPMC12062514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.